Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan and blood test study aims to predict stroke recovery

NCT ID NCT07611136

Knowledge-focused Sponsor: Johannes Dorst Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 180 adults with cerebral small vessel disease to see how their condition changes over time after a stroke. Researchers will use MRI scans and blood tests to track disease progression and look for links to thinking skills, daily function, and stroke recurrence. The goal is to better understand the disease and find new ways to monitor it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict how small vessel disease progresses after a stroke, potentially guiding future treatments.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. Results may not apply to all patients, and biomarkers may not reliably predict disease course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with sporadic, non-genetic cerebral small vessel disease

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Evidence of cerebral small vessel disease on brain MRI, defined as white matter hyperintensities (Fazekas grade 1-3) * Assignment to one of the following study groups based on MRI findings: * cerebral small vessel disease without evidence of an acute ischemic stroke * cerebral small vessel disease with acute lacunar ischemic stroke * cerebral small vessel disease with acute territorial ischemic stroke * Ability to provide written informed consent * Sufficient German language skills to understand study procedures and assessments Exclusion Criteria: * Alternative plausible causes of white matter hyperintensities other than cerebral small vessel disease (e.g. inflammatory central nervous system disorders, leukodystrophies, brain tumors) * Known neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, other dementias) * Acute or recent traumatic brain injury * Contraindications to magnetic resonance imaging * Pregnancy or breastfeeding * Life expectancy of less than one year * Inability to comply with study procedures or follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cerebral Small Vessel Diseases ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarkers Cerebral small vessel disease Stroke Stroke recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Ulm, Department of Neurology, Germany

    RECRUITING

    Ulm, Baden-Wurttemberg, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.